Phase I Open Label Trial of Intraperitoneal Paclitaxel (IPP) in Combination with Intravenous Cisplatin (C) and Oral Capecitabine (X) in Patients with Advanced Gastric Cancer and Peritoneal Metastases

N Abbas; S Vatandoust; T Bright; AC Roy; J Bull; A Scott-Hoy; D Watson; S Gan; CS Karapetis

doi:10.1111/ajco.13022

Phase I Open Label Trial of Intraperitoneal Paclitaxel (IPP) in Combination with Intravenous Cisplatin (C) and Oral Capecitabine (X) in Patients with Advanced Gastric Cancer and Peritoneal Metastases

N Abbas
, S Vatandoust
, T Bright
, AC Roy
, J Bull
, A Scott-Hoy
, D Watson
, S Gan
, CS Karapetis

College of Medicine and Public Health

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	56
Journal	Asia-Pacific Journal of Clinical Oncology
Volume	14
Issue number	S3
DOIs	https://doi.org/10.1111/ajco.13022
Publication status	Published - 18 Jul 2018
Event	Medical Oncology Group of Australia Incorporated Annual Scientific Meeting: New Directions in Personalised Cancer Therapy - Adelaide Convention Centre, Adelaide, Australia Duration: 1 Aug 2018 → 3 Aug 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1111/ajco.13022Licence: In Copyright

Cite this

Abbas, N., Vatandoust, S., Bright, T., Roy, AC., Bull, J., Scott-Hoy, A., Watson, D., Gan, S., & Karapetis, CS. (2018). Phase I Open Label Trial of Intraperitoneal Paclitaxel (IPP) in Combination with Intravenous Cisplatin (C) and Oral Capecitabine (X) in Patients with Advanced Gastric Cancer and Peritoneal Metastases. Asia-Pacific Journal of Clinical Oncology, 14(S3), 56. https://doi.org/10.1111/ajco.13022

@article{ebefc51b779d43e6b0c86ac969c92ba3,

title = "Phase I Open Label Trial of Intraperitoneal Paclitaxel (IPP) in Combination with Intravenous Cisplatin (C) and Oral Capecitabine (X) in Patients with Advanced Gastric Cancer and Peritoneal Metastases",

author = "N Abbas and S Vatandoust and T Bright and AC Roy and J Bull and A Scott-Hoy and D Watson and S Gan and CS Karapetis",

year = "2018",

month = jul,

day = "18",

doi = "10.1111/ajco.13022",

language = "English",

volume = "14",

pages = "56",

journal = "Asia-Pacific Journal of Clinical Oncology",

issn = "1743-7555",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "S3",

note = "Medical Oncology Group of Australia Incorporated Annual Scientific Meeting : New Directions in Personalised Cancer Therapy ; Conference date: 01-08-2018 Through 03-08-2018",

}

Abbas, N, Vatandoust, S , Bright, T, Roy, AC, Bull, J, Scott-Hoy, A, Watson, D, Gan, S & Karapetis, CS 2018, 'Phase I Open Label Trial of Intraperitoneal Paclitaxel (IPP) in Combination with Intravenous Cisplatin (C) and Oral Capecitabine (X) in Patients with Advanced Gastric Cancer and Peritoneal Metastases', Asia-Pacific Journal of Clinical Oncology, vol. 14, no. S3, pp. 56. https://doi.org/10.1111/ajco.13022

Phase I Open Label Trial of Intraperitoneal Paclitaxel (IPP) in Combination with Intravenous Cisplatin (C) and Oral Capecitabine (X) in Patients with Advanced Gastric Cancer and Peritoneal Metastases. / Abbas, N; Vatandoust, S ; Bright, T et al.
In: Asia-Pacific Journal of Clinical Oncology, Vol. 14, No. S3, 18.07.2018, p. 56.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Phase I Open Label Trial of Intraperitoneal Paclitaxel (IPP) in Combination with Intravenous Cisplatin (C) and Oral Capecitabine (X) in Patients with Advanced Gastric Cancer and Peritoneal Metastases

AU - Abbas, N

AU - Vatandoust, S

AU - Bright, T

AU - Roy, AC

AU - Bull, J

AU - Scott-Hoy, A

AU - Watson, D

AU - Gan, S

AU - Karapetis, CS

PY - 2018/7/18

Y1 - 2018/7/18

U2 - 10.1111/ajco.13022

DO - 10.1111/ajco.13022

M3 - Meeting Abstract

SN - 1743-7555

VL - 14

SP - 56

JO - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

IS - S3

T2 - Medical Oncology Group of Australia Incorporated Annual Scientific Meeting

Y2 - 1 August 2018 through 3 August 2018

ER -